The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.

@article{SimardDuquesne1985TheEO,
  title={The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.},
  author={N. Simard-Duquesne and E. Greselin and J. Dubuc and D. Dvornik},
  journal={Metabolism: clinical and experimental},
  year={1985},
  volume={34 10},
  pages={
          885-92
        }
}
  • N. Simard-Duquesne, E. Greselin, +1 author D. Dvornik
  • Published 1985
  • Chemistry, Medicine
  • Metabolism: clinical and experimental
  • Tolrestat(N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl] thioxomethyl]-N-methylglycine; AY-27,773; Alredase) is a potent, structurally novel inhibitor of aldose reductase (AR). In vitro, tolrestat inhibited in dose-dependent fashion the AR from bovine lenses (IC50, 3.5 X 10(-8) mol/L) and the formation of sorbitol in human RBC incubated with glucose (IC50, 3 X 10(-8) mol/L). Upon administration with the diet to rats made galactosemic or diabetic, tolrestat decreased, in a dose-related… CONTINUE READING
    50 Citations
    Aminoguanidine does not inhibit aldose reductase activity in galactose-fed rats.
    • 5
    Tolrestat pharmacokinetics in rat peripheral nerve.
    • 12
    The Effect of Aldose Reductase Inhibition on Erythrocyte Polyols and Galactitol Accumulation in Diabetic Patients
    • 6

    References

    SHOWING 1-10 OF 40 REFERENCES
    CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    • 149
    Prevention of Cataract Development in Severely Galactosemic Rats by the Aldose Reductase Inhibitor, Tolrestat
    • 40
    Aldose reductase inhibition: studies with alrestatin.
    • 60
    ISOLATION AND PROPERTIES OF LENS ALDOSE REDUCTASE.
    • 498
    • PDF
    Metabolic disposition and pharmacokinetics of the aldose reductase inhibitor tolrestat in rats, dogs, and monkeys.
    • 17